...ASN) 2020 Annual Meeting.CE mark for Kantaro’s quantitative COVID-19 serology testsKantaro Biosciences LLC and partner Bio-Techne...

...acquisition by research tools and services company Bio-Techne Corp....
...therapies.According to Luminary co-founder and CEO Jeff Liter, Bio-Techne...
...the coming months Luminary will license from Bio-Techne...

...critically needed cell and gene therapies,” the partners said in a statement. Separately, on Tuesday, Bio-Techne Corp....
...technologies and processes into one manufacturing platform to develop and commercialize cell and gene therapies. Bio-Techne...
...Programmed cell death 1 TGF-β - Transforming growth factor beta Elizabeth S. Eaton, Staff Writer Deerfield Management Bio-Techne Corp. Fresenius...

...in the development of next-generation gene and cell therapies. The first, a joint venture between Bio-Techne...
...technologies and processes into one manufacturing platform to develop and commercialize cell and gene therapies. Bio-Techne Corp....
...S. Eaton, Staff Writer Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Fresenius SE & Co. KGaA Bio-Techne Corp. Wilson...

...cancer tests based on detection of five mRNAs; and the Exosome Diagnostics Inc. unit of Bio-Techne Corp....
...Patents: None issued Companies and Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. Bio-Techne Corp....

...inflammatory cytokine levels in the plasma, liver, lung, spleen and bone marrow. Ongoing work by Bio-Techne Corp....
...TARGET/MARKER/PATHWAY: Interleukin-37 (IL-37; IL-1F7) LICENSING STATUS: Patent application filed by University of Colorado Denver and Bio-Techne Corp....
...18, 2019 doi:10.1073/pnas.1821111116 CONTACT: Charles A. Dinarello, University of Colorado Denver, Aurora, Colo. email: cdinare333@aol.com Claire Quang Bio-Techne Corp. University...

...Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250...
...Bio-Techne Corp. (NASDAQ:TECH), Minneapolis, Minn. Business: Diagnostic, Cancer Jaime De Leon ExoDx Prostate(IntelliScore), Prostate cancer liquid biopsy test (exo106) Bio-Techne Corp. Exosome...

...Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250...
...exosomes and is used to predict whether men have high-risk prostate cancer prior to biopsy. Bio-Techne...
...was off $1.22 to $157.03 on Tuesday. Jaime De Leon ExoDx Prostate(IntelliScore), Prostate cancer liquid biopsy test (exo106) Bio-Techne Corp. Exosome...

...Sam Raha, SVP of strategy and coporate development, will become president of DGG. Research supplier Bio-Techne Corp....

...In September, Bio-Techne Corp. (NASDAQ:TECH) acquired fellow supply and service company Trevigen Inc. (Gaithersburg, Md.) for $11...
...DNA damage and repair. Trevigen Inc., Gaithersburg, Md. Bio-Techne Corp. (NASDAQ:TECH), Minneapolis, Minn. Business: Supply/Service Elizabeth S. Eaton Bio-Techne Corp. Trevigen...